Horizon Sues to Knock Out Depomed’s Anti-Takeover Defense

Updated on

Horizon Pharma Plc sued rival drugmaker Depomed Inc. in hopes of invalidating an anti-takeover defense and clearing the way for its $2 billion hostile buyout bid of the maker of painkillers and anti-seizure medicines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.